Pradžia › Limfoma
Limfoma klinikiniai tyrimai JAV ieško dalyvių
142 tyrimai dėl Limfoma ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Houston, TX34 tyrimai
- Boston, MA33 tyrimai
- New York City, NY33 tyrimai
- Washington, DC23 tyrimai
- Baldwin Park, CA21 tyrimas
- Chicago, IL20 tyrimai
- Durham, NC17 tyrimai
- St. Louis, MO15 tyrimai
- Philadelphia, PA15 tyrimai
- Cleveland, OH14 tyrimai
- Edison, NJ12 tyrimai
- Atlanta, GA12 tyrimai
- Seattle, WA12 tyrimai
- Salt Lake City, UT11 tyrimai
- Rochester, MN11 tyrimai
- Nashville, TN11 tyrimai
- Columbus, OH11 tyrimai
- Miami, FL11 tyrimai
- Pittsburgh, PA10 tyrimai
- Los Angeles, CA10 tyrimai
- Dallas, TX10 tyrimai
- Queens, NY10 tyrimai
- Mountain View, CA9 tyrimai
- Denver, CO9 tyrimai
- Greenburgh, NY9 tyrimai
- Portland, OR9 tyrimai
- Milwaukee, WI9 tyrimai
- Aurora, CO8 tyrimai
- Birmingham, AL8 tyrimai
- Staten Island, NY8 tyrimai
- East Norwalk, CT8 tyrimai
- Cincinnati, OH8 tyrimai
- San Antonio, TX7 tyrimai
- Tampa, FL7 tyrimai
- New Haven, CT7 tyrimai
- New Rochelle, NY7 tyrimai
- Omaha, NE7 tyrimai
- Phoenix, AZ7 tyrimai
- Kansas City, MO6 tyrimai
- Baltimore, MD6 tyrimai
Pagal valstiją
- Ajova6 tyrimai
- Alabama9 tyrimai
- Arizona11 tyrimai
- Arkansas3 tyrimai
- Džordžija16 tyrimai
- Florida25 tyrimai
- Ilinoisas23 tyrimai
- Indianas6 tyrimai
- Kalifornija40 tyrimai
- Kanzasas7 tyrimai
- Kentukis5 tyrimai
- Koloradas16 tyrimai
- Kolumbijos apskritis7 tyrimai
- Konektikutas7 tyrimai
- Masčusetsas33 tyrimai
- Merilendas21 tyrimas
- Minesota14 tyrimai
- Misūris17 tyrimai
- Mičiganas12 tyrimai
- Nebraska7 tyrimai
- New Jersey18 tyrimai
- New York42 tyrimai
- North Carolina22 tyrimai
- Ohio29 tyrimai
- Oklahoma4 tyrimai
- Oregon9 tyrimai
- Pennsylvania24 tyrimai
- South Carolina4 tyrimai
- Tennessee15 tyrimai
- Texas45 tyrimai
- Utah14 tyrimai
- Virginia10 tyrimai
- Washington12 tyrimai
- Wisconsin12 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Renkami dalyviai1 fazė
Amžius nuo 12 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT02917083Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Renkami dalyviaiStebimasis tyrimas
Amžius 3 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT01441089Rutgers University Study of the Genetics of Blood Cancers
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07714044T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05442515A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07015242A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Renkami dalyviai2 fazė
1 Month – 17 Years · Visoms lytims · Atnaujinta 2026-09-30 · NCT04570423Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT07583810Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00006518A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07014293Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT03418038Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT03223610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Renkami dalyviai1/2 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-25 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Renkami dalyviai1 fazė
24 Months – 18 Years · Visoms lytims · Atnaujinta 2026-09-25 · NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Renkami dalyviaiAnkstyvoji 1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT06398457Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT02974647CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-24 · NCT04083495Precise Oncology Interventions in Nutrition and Training (OnPoint)
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT06534918Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT04301076Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.